NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ADCT Stock Alerts $4.45 -0.33 (-6.90%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.41▼$4.6550-Day Range$3.74▼$5.3052-Week Range$0.36▼$6.04Volume296,916 shsAverage Volume746,711 shsMarket Capitalization$368.50 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ADC Therapeutics alerts: Email Address ADC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside68.9% Upside$7.50 Price TargetShort InterestHealthy1.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.20) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.89 out of 5 starsMedical Sector561st out of 907 stocksPharmaceutical Preparations Industry256th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageADC Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.60% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 10.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 1.6 News and Social Media Coverage News SentimentADC Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($2.20) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About ADC Therapeutics Stock (NYSE:ADCT)ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesApril 22, 2024 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Hold" from BrokeragesApril 21, 2024 | americanbankingnews.comGenerex Biotechnology (OTCMKTS:GNBT) versus ADC Therapeutics (NYSE:ADCT) Head-To-Head ContrastApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 19, 2024 | americanbankingnews.comAnalysts Set Expectations for ADC Therapeutics SA's Q1 2024 Earnings (NYSE:ADCT)April 18, 2024 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Short Interest Up 5.7% in MarchApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial ProgressApril 16, 2024 | americanbankingnews.comADC Therapeutics' (ADCT) "Buy" Rating Reaffirmed at HC WainwrightApril 4, 2024 | msn.comADC Therapeutics gains after data for lymphoma therapyApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 4, 2024 | globenewswire.comADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaApril 3, 2024 | globenewswire.comADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024April 1, 2024 | finance.yahoo.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMarch 16, 2024 | finance.yahoo.comUS$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These ResultsMarch 15, 2024 | seekingalpha.comADC Therapeutics SA (ADCT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 ADC Therapeutics SA Earnings CallMarch 13, 2024 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic ResetMarch 13, 2024 | globenewswire.comADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | globenewswire.comADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitMarch 6, 2024 | globenewswire.comADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024March 5, 2024 | globenewswire.comADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingFebruary 27, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 24, 2024 | msn.comADC Therapeutics (ADCT) Price Target Increased by 9.38% to 8.93February 23, 2024 | benzinga.comADC Therapeutics Stock (NYSE:ADCT), Quotes and News SummaryFebruary 21, 2024 | finance.yahoo.comEarnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to DeclineFebruary 20, 2024 | finance.yahoo.comEarnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to DeclineFebruary 15, 2024 | msn.comThe 3 Biotech Stocks That Could Make Your February UnforgettableSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees273Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$11.00 Low Stock Price Target$2.00 Potential Upside/Downside+67.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-240,050,000.00 Net Margins-344.15% Pretax Margin-280.94% Return on Equity-1,313.37% Return on Assets-53.29% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.73 Sales & Book Value Annual Sales$69.56 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-2.33Miscellaneous Outstanding Shares82,810,000Free Float53,498,000Market Cap$371.82 million OptionableOptionable Beta1.73 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 51)M.S., CEO & Director Comp: $1.84MMr. Jose I. Carmona M.B.A. (Age 52)Chief Financial Officer Comp: $884.86kDr. Mohamed Zaki M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $2.41MMs. Lisa Michelle KalleboCorporate Controller & Chief Accounting OfficerDr. Michael Mulkerrin Ph.D. (Age 69)Chief Technical Operations Officer Dr. Patrick van Berkel Ph.D. (Age 56)Chief Scientific Officer Amanda HamiltonInvestor Relations OfficerMr. Peter J. Graham Esq. (Age 57)Chief Legal Officer Ms. Eugenia LitzVice President of Investor Relations & Corporate CommunicationsMs. Kimberly Pope (Age 57)Senior VP & Chief People Officer More ExecutivesKey CompetitorsLarimar TherapeuticsNASDAQ:LRMRLexicon PharmaceuticalsNASDAQ:LXRXAvid BioservicesNASDAQ:CDMONeurogeneNASDAQ:NGNEAnnexonNASDAQ:ANNXView All CompetitorsInstitutional OwnershipHennion & Walsh Asset Management Inc.Bought 4,700 shares on 4/17/2024Ownership: 0.086%Affinity Asset Advisors LLCSold 86,460 shares on 2/13/2024Ownership: 0.000%Saxony Capital Management LLCBought 20,623 shares on 1/29/2024Ownership: 0.000%View All Institutional Transactions ADCT Stock Analysis - Frequently Asked Questions Should I buy or sell ADC Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADCT shares. View ADCT analyst ratings or view top-rated stocks. What is ADC Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $11.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 68.9% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts. How have ADCT shares performed in 2024? ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT shares have increased by 167.5% and is now trading at $4.44. View the best growth stocks for 2024 here. Are investors shorting ADC Therapeutics? ADC Therapeutics saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 888,100 shares, a drop of 10.6% from the March 31st total of 993,100 shares. Based on an average daily trading volume, of 733,600 shares, the short-interest ratio is presently 1.2 days. Approximately 1.6% of the company's shares are short sold. View ADC Therapeutics' Short Interest. When is ADC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ADCT earnings forecast. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) announced its earnings results on Wednesday, March, 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.56. The business had revenue of $16.79 million for the quarter, compared to the consensus estimate of $16.58 million. ADC Therapeutics had a negative net margin of 344.15% and a negative trailing twelve-month return on equity of 1,313.37%. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX). When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%). How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ADCT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
